ð§Ž ã¢ãŒã©ã€ã³é žã¯äœããããïŒèµ€ã¿ã»ãããã»è²çŽ æ²çã«åŒ·ãçç±ïœæ¯ç©Žãšå¯äœçšã®éçã解説
ã²ããã
ð§Ž ã¢ãŒã©ã€ã³é žã®å¹æïŒèµ€ã¿ã»ãããã»ãããè·¡ã1æ¬ã§çããå®å掟æåïœæ¯ç©Žã»èæã»å¯äœçšãŸã§è§£èª¬
ð¯ å ã«çµè«
ã¢ãŒã©ã€ã³é žã¯ãé ãïŒäžç¹è¿ç±åïŒãããããè²çŽ æ²çã§æ¯èŒçæžããããå€çšæåã§ããç¹ã«é ãã¯ãšããã³ã¹ã匷ããããããšèæã»ççåŸè²çŽ æ²çã¯ãæåãªéžæè¢ããšèšããããäžæ¹ãæ¯ç©Žã®éãããããåç¬ã§åŒ·ãæ¹åãã䞻圹ãšãŸã§ã¯èšãã«ããã®ãçŸç¶ã§ã2, 4, 8, 11ã
æåŸ å€ãã²ãšèšã§ãŸãšãããšãèµ€ã¿ã»ããããã»è²ã ã©ã«ã¯çãããããšã€ãžã³ã°ãæ¯ç©Žã®èŠãç®ã«ã¯æ§ããã§ããå³å¹åãšãããããåºæ¿ã調æŽããªããæ°é±éåäœã§èŠãŠããæåã ãšèãããšçŸå®ã«åããŸã4, 5, 6ã
å®å šæ§ã®é¢ã§ããã¢ãŒã©ã€ã³é žã¯å€çšåŸã®å šèº«åžåãå°ãããè¡äžæ¿åºŠãé£äºãäœå ç±æ¥ã®éåžžç¯å²ã倧ããè¶ ãã«ããããšãå ¬åŒã©ãã«ã§ç€ºãããŠããŸããã ãããæ¯èŒçå®å¿ããŠäœ¿ããããããšèšãããããã®ã§ãããããã¯å¯äœçšããŒããšããæå³ã§ã¯ãªããéãå šèº«å¯äœçšã¯èµ·ããã«ããäžæ¹ã§ã屿ã®åºæ¿ã¯èµ·ãããããšããæŽçãæ£ç¢ºã§ã5, 12ã
äžç¹ã»è¿ç±ã䌎ãã¿ã€ãã§ã¯æ ¹æ ã匷ãã§ãã
ã¬ã€ãã©ã€ã³ã§æ²»çéžæè¢ã«å ¥ãäžæ¹ãäžèœã§ã¯ãããŸããã
èæããããè·¡ã®è²ã ã©ã§åè£ã«ãªããŸãã
è©°ãŸã察çã®è£å©ã¯ããåŸãŸããã䞻圹çŽã®æ ¹æ ã¯åŒ±ãã§ãã
ð ãã®èšäºã®åæ
ããã§æ±ãã®ã¯äžè¬åãã®æŽçã§ãã蚺æãåŠæ¹ã®ä»£ããã§ã¯ãªãã匷ãåºæ¿ãæªåãåŠåš ã»æä¹³äžãæ°èŠå°å ¥ã®äžå®ãããå Žåã¯å»çè ã«çžè«ããåæã§èªãã§ãã ããã
ã¢ãŒã©ã€ã³é žã¯äœãã§ããæåã
ã¢ãŒã©ã€ã³é žã¯ãç®èç§é åã§é·ã䜿ãããŠããå€çšæåã§ãæççãè§åã®èª¿æŽãæèãã¡ã©ãã³çæã®æå¶ãšããè€æ°ã®æ¹åãã説æãããããšãå€ãæåã§ããã€ãŸããã²ãšã€ã®æ©ã¿ã«ã ãåºãããšãããããèµ€ã¿ã»è©°ãŸãã»è²ã ã©ã®å¢ç®ã«ããæ©ã¿ã§äœ¿ããããã¿ã€ãã§ã3, 10ã
èµ€ã¿ãããªã€ãã®åå ã«ãªãåå¿ãèœã¡çããã
æ¯ç©Žã¥ãŸããèµ·ããã«ãããã
ãããé¢é£ã®ç°å¢ãæŽãã
PIHãèæã®èŠãæ¹ã«é¢ããå¯èœæ§ããã
ð¡ èŠæ¹ã®ã³ã
ãã®æåãäžèšã§èšããªããããããçšããçŸçœçšããèµ€ã¿çšãã®çãäžãããã«ããæåã§ããã ãããããã©ã®æ©ã¿ã§äœ¿ãã®ããå ã«æ±ºããªããšãæåŸ å€ããŒããããããªããŸãã
æ©ã¿å¥ã®ãšããã³ã¹ãå ã«äžèЧã§èŠã
ãŸãã¯å šäœåã§ããããã§ã®åŒ·ãã¯ã系統çã¬ãã¥ãŒã»ã¡ã¿è§£æã»RCTã»ã¬ã€ãã©ã€ã³ã§ã®äœçœ®ã¥ãããŸãšããå®çšçãªç®å®ã§ãã
| æ©ã¿ | æ ¹æ ã®åŒ·ã | ã©ããŸã§èšããã | å®åäžã®äœçœ®ã¥ã |
|---|---|---|---|
| é ãïŒäžç¹è¿ç±åïŒ | é« | å€çšã¢ãŒã©ã€ã³é žã¯æå¹æ§ã®æ ¹æ ã匷ã | 第äžåè£ã«ãªãããã2, 5 |
| ãããïŒé¢ç°ã»ççïŒ | äž | ã¬ã€ãã©ã€ã³ã§æ²»çéžæè¢ã ããåç¬ã§æåŒ·ãšã¯èšãã«ãã | æåãªéžæè¢ã®ã²ãšã€1, 3, 4, 7, 10 |
| èæã»è²çŽ æ²ç | äžããã匱 | ãã€ããããã³æ¯èŒã§è¯å¥œãªå¯èœæ§ã¯ããããã°ãã€ãããã | èåºæ¿ãæããã人ã®åè£8, 10 |
| ãããè·¡ã®èµ€ã¿ã»è¶è² | ãã匱ãäž | 12é±éRCTã¯ååãã ããèç©ã¯ãŸã å€ããªã | ç¶ç¶åæã®è·¡ã±ã¢åè£9 |
| æ¯ç©Žã»ç®è | 匱 | è©°ãŸããããã€ãã®è£å©ã¯ããåŸãããæ¯ç©Žã®éãèªäœã®åŒ·ã詊éšã¯å°ãªã | è©°ãŸãç³»æ¯ç©Žã®è£å©3, 10 |
| ããã»ãšã€ãžã³ã° | éåžžã«åŒ±ã | äžå®æ¡ä»¶ãæºãã驿 Œç ç©¶ãä¹ãã | éåºŠãªæåŸ ã¯çŠç©11 |
é ããšãããã§ã¯ã©ã䜿ãããã
é ãã¯æãçãããé å
ã¢ãŒã©ã€ã³é žãèªããšãããã¡ã°ããšããã³ã¹ãã¯ã£ããããŠããã®ã¯äžç¹ã»è¿ç±ã䌎ãé ãã§ããCochrane ã®æŽçã§ã¯æ ¹æ ã®è³ªãé«ããç±³åœã®15%ã²ã«ã®ã©ãã«ã§ãã軜床ããäžç床ã®é ãã«ãããççæ§äžç¹ã»è¿ç±ãäž»ãªå¯Ÿè±¡ãšããŠç€ºãããŠããŸã2, 5ã
ããã§å€§äºãªã®ã¯ããèµ€ã¿å šè¬ã«å¹ãããšèšãåããªãããšã§ããããããã䌎ããªãèµ€ã¿ã ãã®ã¿ã€ãã¯åãå俵ã§ã¯è©äŸ¡ãã«ãããã¬ãŒã¶ãŒãè¡ç®¡åçž®ç³»ã®æ²»çãåã«æ¥ãå ŽåããããŸã1, 5ã
ãããã¯éžæè¢ãšããŠæåãã§ãäžèœã§ã¯ãªã
ãããã§ã¯ãæ¥æ¬ã»ç±³åœã»è±åœã®ã¬ã€ãã©ã€ã³ã§ã¢ãŒã©ã€ã³é žãæ²»çéžæè¢ã«å ¥ã£ãŠããŸããé¢ç°ãççæ§ç å€ãããã«ãããåŸã®è²çŽ æ²çãŸã§äžç·ã«èŠãããšãã«çžæ§ãããæåã§ã1, 3, 4ã
äžæ¹ã§ããããã¯ãŒã¯ã¡ã¿è§£æã§ã¯ã軜ãäžççãããã«ãããåç¬äœ¿çšã®å¹æãæ§ãããäžç¢ºå®ã«èŠããè§£æããããŸããã€ãŸããå¹ããªããšãããããåç¬ã§å§åçãªåãæã§ã¯ãªããçµã¿åããæ²»çã®äžè§ãšããŠçè§£ããæ¹ãçŸå®çã§ã7, 10ã
ð§ ãããã§éžã³ããã人
è©°ãŸããççã«å ããŠããããè·¡ã®è²ã ã©ãæ°ã«ãªã人ããããã¯åºæ¿ã®åŒ·ãæ²»çãæ¯æ¥ã¯äœ¿ãã«ãã人ã§ã¯ãã¢ãŒã©ã€ã³é žã¯æŽçããããåè£ã§ãã
è²ã ã©ã»ãããè·¡ã§ã¯ã©ãèŠãã
èæã»è²çŽ æ²çã¯ãåè£ããšããŠã¯ååãã
èæã§ã¯ãã¢ãŒã©ã€ã³é žãšãã€ããããã³ãæ¯èŒããã¡ã¿è§£æã§ãMASI ã®æ¹åãããè¯ãå¯èœæ§ã瀺ãããŠããŸãããã ããç ç©¶ã®ã°ãã€ããè©äŸ¡é ç®ã®éãã倧ããã誰ã«ã§ãæç¢ºã«äžåããšãŸã§ã¯èšãã«ããé åã§ã8, 10ã
å®åçã«ã¯ãåºæ¿ã®åŒ·ãçŸçœæ²»çãåããªã人ã®éžæè¢ãšããŠæžããšãã©ã³ã¹ãåããããã§ããèæã¯æ¥çŒãæ¢ããæ©æŠå¯Ÿçã®åœ±é¿ã倧ãããããæååç¬ã§èªãåããªãæ¹ãå®å šã§ã3, 8ã
ãããè·¡ã®èµ€ã¿ã»è¶è²ã¯ææã ãç©ã¿äžãéäž
PIEã»PIH ã«é¢ããŠã¯ã15%ã²ã«ã12é±é䜿ã£ãRCTã§ãè©äŸ¡ã¹ã³ã¢ãè²ã®ææšã®æ¹åãå ±åãããŠããŸããæ¹åæ§ã¯ããªãè¯ããã®ã®ããŸã ç ç©¶æ°ã¯å€ããªããããçŸæç¹ã§ã¯ææãªåè£ãšè¡šçŸããã®ãã¡ããã©ããã§ã9ã
æ¯ç©Žã»ç®èã»ããã¯æåŸ å€ãäžããŠèªã
æ¯ç©Žæ©ã¿ã§ã¢ãŒã©ã€ã³é žãæ€èšãããªããçãã¹ãã¯ãéãããã®ãã®ãããè©°ãŸãã»ããã€ãã»ãããã«äŒŽãç®ç«ã¡ã§ããè§å調æŽã«ãã£ãŠé¢ç°ãæžããçµæãšããŠèŠãç®ãå°ãæŽãå¯èœæ§ã¯ãããŸãããæ¯ç©Žã®é倧ãäž»è©äŸ¡ã«ãã匷ã詊éšã¯å€ããããŸãã3, 10ã
ç®èã«é¢ããå°èŠæš¡ããŒã¿ã¯ãããã®ã®ãå€§èŠæš¡ãªèšåºæ ¹æ ãååãšã¯èšããŸãããããã«ããããããªã«ã€ããŠã¯ãäžå®æ¡ä»¶ãæºãã驿 Œç ç©¶ãã»ãšãã©èŠåœãããªããšæŽçãããŠããŸã11ã
çœã»é»ãããã絡ãã¿ã€ãã§ã¯è£å©ã«ãªãåŸãŸãã
䞻圹çŽãšãããããããŸãã®æåŸ å€ã§ãã
ãšã€ãžã³ã°ã±ã¢ã®äžå¿æåãšããŠèªãã®ã¯ç¡çããããŸãã
äœ¿ãæ¹ã®ç®å®
å»ççšã®èšèŒãã¬ã€ãã©ã€ã³ã§ã¯ãã¢ãŒã©ã€ã³é žã¯ãããã15%ãŸãã¯20%ã®è£œå€ã§æ±ãããåºæ¬ã¯1æ¥2åãåå°ã§ãããã ããææèã¯æåããå šåã§å¡ããªãæ¹ãç¶ãããããæåã®1é±éã¯1æ¥1åããå§ããèãæ¹ãçŸå®çã§ã4, 5, 6ã
ç ç©¶ãšã¬ã€ãã©ã€ã³ã§ããåºãŠããç¯å²ã§ãã
æå€ãäžè¬çã§ãããåºæ¿ãããã°æžãããŸãã
ææèã¯å°ãªãéå§ã®æ¹ãç¶ç¶ããããã§ãã
æ©ãããå€å®ã ãšãå¹ãåã«ããããããªããŸãã
æ¯èŒçå®å¿ããŠäœ¿ãããããšèšãããçç±
ã¢ãŒã©ã€ã³é žããæ¯èŒçå®å šæ§ãé«ãããšèšãããããçç±ã¯ãå¹ãã®ã«åŒ·ãããå šèº«æé²ãèµ·ããã«ããããšã§ããFDA ã® 15%ã²ã«ã©ãã«ã§ã¯ã8é±é以äžäœ¿ã£ãæ£è ã®å¹³åè¡äžæ¿åºŠã¯ãåºå€ã ãã䜿ã£ã矀ãé£äºã»äœå 代è¬ç±æ¥ã®éåžžç¯å²å ã«åãŸã£ãŠããŸããã20%ã¯ãªãŒã ã®ã©ãã«ã§ããå€çšåŸã®è¡äžæ¿åºŠãå°¿äžææ³ã¯ããŒã¹ã©ã€ã³ãšææå·®ããªããšãããŠããŸã5, 12ã
ããã«ã15%ã²ã«ã®äººã§ã®ç®èå®å šæ§è©Šéšã§ã¯ãå æ¯æ§ãå ã¢ã¬ã«ã®ãŒã¯å ±åãããŠããŸãããåŠåš ã»æä¹³ã§ããFDA ã©ãã«ã¯ãæå°éã®å šèº«åžåã§ãéåžžã®äœ¿çšã§ã¯èå ãæä¹³å ãžã®æé²ã¯èµ·ããã«ããããšæŽçããŠãããAAD ã®äžè¬åãæ å ±ã§ãåŠåš äžã«æ¯èŒç䜿ããããæåãšããŠæ±ãããŠããŸã3, 5ã
è¡äžæ¿åºŠã¯é£äºãäœå ç±æ¥ã®éåžžç¯å²å ã«åãŸããããã§ãã
15%ã²ã«ã®äººã§ã®ç®èå®å šæ§è©Šéšã§ã¯å æ¯æ§ã»å ã¢ã¬ã«ã®ãŒãªãã§ããã
ãã ãæ°èŠå°å ¥ãåºç¯å²äœ¿çšã¯èªå·±å€æã§é²ããªãæ¹ãå®å šã§ãã
å®å¿ææãå€ããŠããããªã€ãã也ç¥ãŸã§ã¯ãŒãã«ã¯ãªããŸããã
ð§ ã€ãŸãã©ãèããã°ããã
ã¢ãŒã©ã€ã³é žã¯ããæ»ããæåãªã®ã«å¯äœçšãå°ãªãããšããããããå šèº«æ§ã®éãå¯äœçšã¯èµ·ããã«ãããå±æåºæ¿ã管çããªããç¶ãããããã¿ã€ãã§ãããã®ãã©ã³ã¹ããããããé ããè²çŽ æ²çã®ã©ãã«ã䜿ããããçç±ã§ã3, 5, 12ã
å¯äœçšãšå®å šæ§
å¯äœçšã®äžå¿ã¯ãå šèº«æ§ã®éããã®ããå¡ã£ãå Žæã®åºæ¿ã§ãããšãã«éå§çŽåŸã¯ãããªã€ããããã¿ã也ç¥ãèµ€ã¿ãåºããããããã§ç¡çããããšé¢è±ãããããªããŸã5, 6ã
ãã ããããã§ããåŒçšãããæ°åã¯é ãåã 15%ã²ã«ã®ãã®ã§ãããããåã 20%ã¯ãªãŒã ã®ç±³åœã©ãã«ã§ã¯ãäž»ãªå¯äœçšã¯ãããã1ã5%ã§ããããå€ãã mild and transientãšãããŠããŸããã€ãŸããã¢ãŒã©ã€ã³é žå šäœãäžåŸã«ãåºæ¿ã匷ãããšèªãã®ã§ã¯ãªãã補å€ãšå¯Ÿè±¡çŸæ£ã§èŠãæ¹ãå€ãããšçè§£ããæ¹ãæ£ç¢ºã§ã5, 12ã
| å¯äœçšïŒé ã15%ã²ã«ïŒ | èµ·ãããããã®ç®å® | èŠæ¹ |
|---|---|---|
| ããªããªã»çŒç±æ | çŽ29% | æåã®æ°é±ã«åºããã代衚çç¶ã§ã5 |
| ããã¿ | çŽ11% | 也ç¥ãšäžç·ã«åºãããšããããŸã5 |
| 也ç¥ã»ç®ãã | çŽ8% | é »åºŠèª¿æŽãšä¿æ¹¿ã§è»œããªãããšãå€ãã§ã5, 6 |
| èµ€ã¿ã»åºæ¿æ | çŽ4% | ããšããšã®ç å€ãšèŠåãã«ããããšããããŸã5 |
ð ïž åºæ¿ãåºããšãã®å®ç³
éãæžããã1æ¥1åã«èœãšããæ°æ¥äŒããä¿æ¹¿ãè¶³ãã®4ã€ãåºæ¬ã§ãããããªããŒããç¶è¡ãã®äºæã«ããªãæ¹ããæ»ããããã±ãŒã¹ãå€ãã§ã5, 6ã
éã«èšããšãããªã€ããåºãããçžæ§ææªãšå³æããªããŠããã±ãŒã¹ããããŸããé »åºŠèª¿æŽã§ä¹ãåãããªããæ¯èŒçç¶ããããæåã§ã6, 12ã
åŠåš ã»æä¹³ã»å¹Žéœ¢å¥ã®æ³šæç¹
-
åŠåš äž
AAD ã®äžè¬åãæ å ±ã§ã¯æ¯èŒçå®å šå¯ãã«æ±ãããFDA ã® 15%ã²ã«ã©ãã«ã§ãæå°éã®å šèº«åžåã§èå æé²ã¯èµ·ããã«ãããšæŽçãããŠããŸãããã ããååãªåŠå©Šè©Šéšãå€ãããã§ã¯ãªãã®ã§ãæ°èŠå°å ¥ã¯èªå·±å€æã§å§ããã䞻治å»ãšçžè«ãå®å šã§ã3, 5, 6ã
-
å°å ã»ææ¥æ
20%ã¯ãªãŒã ã®æ å ±ã§ã¯ã12ã18æ³ã¯å€§ããªçšé調æŽãªãã12æ³æªæºã¯ååãªå®å šæ§ã»æå¹æ§ããŒã¿ã確ç«ããŠããªããšãããŠããŸã6ã
-
é«éœ¢è
ç¹åããç ç©¶ã¯å€ããããŸããã也ç¥ãããããèãããšãäœé »åºŠã¹ã¿ãŒããšä¿æ¹¿éèŠã®éçšãç¡é£ã§ã6ã
â ãŸãšã
ã¢ãŒã©ã€ã³é žããã¡ã°ãèªç¶ã«å§ããããã®ã¯ãé ãã®ããããããããããããè·¡ãèæã®è²ã ã©ã§ããéã«ãæ¯ç©Žã®éããããã匷ãæã¡åºãæåãšããŠã¯æ ¹æ ã匱ããçã£ã衚çŸã¯é¿ããæ¹ãå®å šã§ã2, 8, 11ã
éçšã®ã³ãã¯ãåºæ¿ãã³ã³ãããŒã«ããªãã6ã12é±ã§èŠãããšããããŠè²ã ã©ãçããªãæ¥çŒãæ¢ããŸã§å«ããŠäœ¿ãããšã§ããæåã®åŒ·ããããç¶ããããèšèšãã©ãããçµæãåããããã§ã4, 5, 6ã
åèæç®
- æ¥æ¬ç®èç§åŠäŒ. ãå°åžžæ§ç€ç¡ã»é ç¶æ²»çã¬ã€ãã©ã€ã³ 2023ã. ã¢ãŒã©ã€ã³é žå€çšã®æšå¥šåºŠãæŽçããåœå ã¬ã€ãã©ã€ã³ã
- Cochrane. âInterventions for rosacea.â å€çšã¢ãŒã©ã€ã³é žã®æå¹æ§ã«é«å質ãšããã³ã¹ããããšæŽçããã¬ãã¥ãŒã
- American Academy of Dermatology. ãããèšåºã¬ã€ãã©ã€ã³ã®ãã€ã©ã€ãããã³äžè¬åã解説. ã¢ãŒã©ã€ã³é žã®äœçœ®ã¥ãããããåŸè²çŽ æ²çãåŠåš äžã®æ±ãã«é¢ããæ å ±ã
- NICE. âAcne vulgaris: managementâ (NG198). å€çšã¢ãŒã©ã€ã³é ž 15% / 20% ã®äœçœ®ã¥ãã12é±éã³ãŒã¹ãäœµçšæ²»çã®éžæè¢ã瀺ãè±åœã¬ã€ãã©ã€ã³ã
- U.S. Food and Drug Administration. 15% azelaic acid gel label. é ãã§ã®å¯äœçšé »åºŠãäœè²çŽ åãç²èåºæ¿ãªã©ã®æ³šæäºé ãèšèŒããã©ãã«ã
- Skinoren 20% Cream SmPC. 1æ¥2å䜿çšãææèã¯1æ¥1åéå§ãåŠåš ã»æä¹³ãå°å ã®æ±ããªã©ã瀺ããè±åœæ·»ä»ææžçžåœè³æã
- Mavranezouli I, et al. 2022. 軜ãäžçç / äžççãéçãããã«ãããæ²»çã¯ã©ã¹æ¯èŒã®ãããã¯ãŒã¯ã¡ã¿è§£æã
- Albzea A, et al. 2023. èæã§ã¢ãŒã©ã€ã³é žãšãã€ããããã³ãæ¯èŒããã¡ã¿è§£æã
- Shucheng et al. 2024. ãããåŸ PIE / PIH ã«å¯Ÿãã 15% ã¢ãŒã©ã€ã³é žã²ã« 12é±éã®RCTã
- Acta Dermato-Venereologica. 20%ã¯ãªãŒã ã®ããã詊éšãèæè©ŠéšãèŠçŽããã¬ãã¥ãŒè³æã
- King et al. 2023. ã¹ãã³ãšã€ãžã³ã°æèã§ã®ã¢ãŒã©ã€ã³é žã®ç³»çµ±çã¬ãã¥ãŒãããçãè©äŸ¡ãã驿 Œç ç©¶ã®äžè¶³ãææã
- U.S. Food and Drug Administration. AZELEX cream, 20% label (2024). å€çšåŸã®è¡äžæ¿åºŠã»å°¿äžææ³ãããŒã¹ã©ã€ã³ãšææå·®ãªããäž»ãªå¯äœçšã¯æŠã1ã5%ã§å€ãã mild and transient ãšèšèŒã
ã²ããã
èªç¶ã奜ããå±±ã奜ããäœã«ãããã¶ãã¯ãã奜ãã ããããã話ã¯äžæ¬¡è«æããŒã¹ã§ãããããAIãšãã£ããã«èªã¿ããããå±ãããŸããïŒèã«ã¯ãããããæ ¹æ ã«ã¯ãã³ãããïŒ
é¢é£èšäº
ð§ çããã®å¹æïŒè質ã»è¡å§ã»è žå ç°å¢ãšã®é¢ä¿ïœé£ã¹æ¹ã»ç®ã®äœ¿ãæ¹ã»æ³šæç¹
ð² è±ç²ç察çã®ç§åŠïŒé£äºã»éåã»ç¡ç ã§çç¶ãåãããæ¹æ³ïœä»æ¥ããã§ããå·¥å€«ãšæ³šæç¹